Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Oxford Immunotec Global plc. (8/30/17). "Press Release: Oxford Immunotec to Present at the Baird 2017 Global Healthcare Conference". Oxford & Marlborough, MA.

Organisations Organisation Oxford Immunotec Global plc (Nasdaq: OXFD)
  Group Oxford Immunotec (Group)
  Organisation 2 Baird (Group)
Products Product Baird Global Healthcare Conference 2017 New York
  Product 2 T-SPOT®.TB test
Index term Index term Oxford Immunotec–Baird: investor conference, 201709 supply service Oxford Immunotec presents at Baird 2017 Global Healthcare Conference in NY
Persons Person Altieri, Richard M. (Rick) (Oxford Immunotec 201311 CFO)
  Person 2 Koski, Karen (Oxford Immunotec 201706– Head of Strategy + Investor Relations)
     


Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that Rick Altieri, Chief Financial Officer, will present at the Baird 2017 Global Healthcare Conference on Wednesday, September 6, 2017, at 2:35 p.m. ET at the InterContinental New York Barclay Hotel in New York, NY.


About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions. The Company’s first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China. The Company’s second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. Also obtained through the acquisitions is the Company’s third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the Company’s fourth intended product line focused on the transplantation market. In addition to these four product lines, the Company has additional active development programs in other immune-regulated conditions. The Company is headquartered near Oxford, U.K. and in Marlborough, Mass. Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of Immunetics, Inc.


CONTACT:

For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

   
Record changed: 2017-09-06

Advertisement

Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for Oxford Immunotec (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnering Open 600x60px




» top